Skip to main content

Table 1 Patient demographics and disease characteristics (n = 31)

From: Long term impact of CTLA4 blockade immunotherapy on regulatory and effector immune responses in patients with melanoma

Variable Number of patients (%)
Median age, years (range) 54 (40–87)
Cutaneous primary 25 (81)
Unknown primary 1 (3)
Mucosal 5 (16)
Gender
 Female 10 (32)
 Male 21 (68)
Performance status
 0 10 (32)
 1 21 (68)
Prior adjuvant high-dose IFN 10 (32)
AJCC stage
 IIIB 6 (19)
 IIIC 25 (81)